Is Cagrisema from Lumera Labs HPLC verified?

Yes. Every Cagrisema lot Lumera Labs ships is HPLC-purity tested at synthesis and retested by Janoshik Analytical before release. The lot-specific Certificate of Analysis is published on the Lab Results page.

Is Cagrisema sold for human use?

No. Cagrisema is sold strictly as a laboratory reference standard for in-vitro research. It is not approved by Health Canada or the FDA for human use. Every order requires a research-use declaration.

How is Cagrisema shipped?

Cagrisema is lyophilized at synthesis, sealed under nitrogen, and shipped from Kelowna, BC at -20 C through cold-chain insulated packaging via Canada Post Xpresspost. Free shipping over $200 CAD. 24-48h transit Canada-wide.

Where can I see the COA for Cagrisema?

Each shipment includes a lot-specific Certificate of Analysis. The current lot's COA is also published at https://lumerapeptide.com/lab-results/ and can be cross-referenced by the batch number printed on each vial.

Home / Catalog / Metabolic / Cagrisema 10 mg

4.9 · 34 researcher reviews

Metabolic · Cagrilintide + Semaglutide

Cagrisema

SKU LUM-CAGSEM-10 · Pre-blend · Mixed (3735.83 + 4113.58 g/mol) · CAS Mixed (1415456-99-3 / 910463-68-2)

A pre-blended amylin analog (cagrilintide) plus GLP-1 receptor agonist (semaglutide). Studied as a dual-incretin/amylin-axis research compound.

Purity (HPLC): ≥ 99.3%
Net peptide: 5.00 mg ± 2%
Endotoxin: < 0.5 EU/mg
Format: Lyophilized vial
Storage: −20 °C, desiccated
Shelf life: 24 months from MFG

$150CAD / 10 mg vial

In stock · Lot 26-A031

Bulk 10+: $24 / vial

Add $200 for free cold-chain shipping

HPLC + MS verified per lot
Cold-chain to your door
COA bundled with shipment
Lot retains kept 5 years

Overview

Cagrisema combines cagrilintide (a long-acting amylin/calcitonin-receptor analog) with semaglutide (a long-acting GLP-1 receptor agonist) at a fixed mass ratio. The pairing investigates synergistic suppression of feeding and gastric emptying through complementary pathways: amylin-receptor signaling and GLP-1R activation.

Each component meets ≥ 99% HPLC purity independently before co-lyophilization. Vials are sealed under nitrogen and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

Combinatorial amylin + GLP-1 receptor activation studies, comparative cAMP and β-arrestin recruitment versus monotherapy, and in-vivo metabolic phenotype models.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

Parameter	Value
Sequence	Cagrilintide + Semaglutide co-formulation
Molecular formula	Pre-blend
Molecular weight	Mixed (3735.83 + 4113.58 g/mol)
CAS number	Mixed (1415456-99-3 / 910463-68-2)
Length	Pre-blend (32 + 31 residues)

Quality

Test	Specification
HPLC purity	≥ 99.0% (lot LM-2625: ≥ 99.0% per component)
Mass confirmation	ESI-MS within 0.5 Da
Net peptide content	≥ 80% by AAA
Endotoxin	< 0.5 EU/mg (LAL)
Bioburden	< 10 CFU/g
Residual TFA	< 1.0%

Lot LM-2625

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

Method	Result
RP-HPLC at 220 nm	≥ 99.0% per component main peak
ESI-MS (positive)	Two peaks: 3735.8 + 4113.6 Da
Amino acid analysis	82.1% net peptide
LAL endotoxin	< 0.05 EU/mg
Karl Fischer (water)	2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Lau DCW et al. Once-weekly cagrilintide for weight management in adults with overweight or obesity. Lancet. 2021;398(10317):2160–2172.

Frias JP et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg. Lancet. 2023;402(10403):720–730.

Enebo LB et al. Cagrilintide plus semaglutide combination. Lancet. 2021;397(10286):1736–1748.

Citing this material

Cagrisema reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-CAGSEM-10, Lot 26-A031.

Related · Metabolic axis

Often paired in studies.

View catalog →

GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →

Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →

Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →

Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Cagrisema

Overview

Research applications

Identity

Quality

Lot LM-2625

Verification

Reconstitution

Storage after reconstitution

Selected references

Citing this material

Often paired in studies.

Tirzepatide

Retatrutide

Cagrisema

AOD-9604

Why Lumera